APA (7th ed.) Citation

NM, L., WH, S., M, G., AA, G., DJ, D., H, K. T., . . . MW, T. (2022). Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(Suppl 2), S159. https://doi.org/10.1093/cid/ciac439

Chicago Style (17th ed.) Citation

NM, Lewis, et al. "Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 75, no. Suppl 2 (2022): S159. https://doi.org/10.1093/cid/ciac439.

MLA (9th ed.) Citation

NM, Lewis, et al. "Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 75, no. Suppl 2, 2022, p. S159, https://doi.org/10.1093/cid/ciac439.